Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-8951993

RESUMEN

Cyclosporine (CsA) (37.4 mumol/kg per day for 7 days) treated female Wistar rats exhibited significantly decreased creatinine clearance (Ccr) and body weight loss (BWL), but had neither proteinuria (PU) nor alteration in their urine volume (V). Light microscopic (LM) sections of rat kidneys showed that all kidneys were affected by lesions, mainly diffuse vacuolization. These changes were associated with decreased urinary excretion ratios of 6-ketoprostaglandin F1 alpha to thromboxane B2 (6kPGF1 alpha/TXB2) and prostaglandin E2 to TXB2 (PGE2/TXB2). When OKY-046, a TXA2-synthetase inhibitor or nifedipine (NFD), a calcium channel blocker and an antagonist of endotheline (ET), were administered in addition to CsA, they restored Ccr and increased urine V but they did not prevent BWL. LM sections showed that only 5 or 7 out of 9 kidneys of animals were affected, respectively. These changes were associated with prevention of the diminished ratios of urinary PGE2/TXB2 and 6kPGF1 alpha/TXB2 mainly in the OKY-046 treated animals. In conclusion, our results suggest that inhibitors of TXA2 or antagonists and/or inhibitors of endothelin play a protective role in the development of the dysfunction induced by CsA. However, the protection observed using OKY-046 and NFD did not reach that obtained by evening primrose oil (EPO) or Ketanserine (KTS), substances which prevented the fall of Ccr and BWL. Furthermore, with these protective agents only 5 out of 9 kidneys were affected and the lesions were of minor importance.


Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Ciclosporina/toxicidad , Inhibidores Enzimáticos/uso terapéutico , Inmunosupresores/toxicidad , Metacrilatos/uso terapéutico , Nifedipino/uso terapéutico , Insuficiencia Renal/prevención & control , Animales , Creatinina/farmacocinética , Interacciones Farmacológicas , Eicosanoides/orina , Ácidos Grasos Esenciales/uso terapéutico , Femenino , Ketanserina/uso terapéutico , Pruebas de Función Renal , Túbulos Renales/patología , Ácidos Linoleicos , Tasa de Depuración Metabólica , Oenothera biennis , Aceites de Plantas , Ratas , Ratas Wistar , Ácido gammalinolénico
2.
Artículo en Inglés | MEDLINE | ID: mdl-8146206

RESUMEN

Administration of cyclosporine (CsA), 37.4 microM (45 mg)/Kg, per day for 7 days, to Wistar rats, induced decreased creatinine clearance (Ccr) and body weight loss (BWL), but it did not induce proteinuria. These changes were associated with enhanced urinary thromboxane B2 (TXB2) and diminished 6-keto-PGF1 alpha (6kPGF1 alpha) and prostaglandin E2 (PGE2) excretions. The augmentation in TXB2 and the decrease in PGs highly diminished the ratios of 6kPGF1 alpha/TXB2 and PGE2/TXB2. In microscopic sections all of the kidneys were affected to variable degrees. When CsA was administered to animals fed for 70 days, prior to the experiment, on standard chow (SC) containing evening primrose oil (EPO) or fish oil (FO), 1% and 10% respectively (EPO contained 9% gamma-linolenic acid (GLA) and FO 5.6% eicosapentaenoic acid (EPA)), the nephrotoxic effect of CsA was partially prevented. These changes were accompanied by increased ratios of urinary 6kPGF1 alpha/TXB2 and PGE2/TXB2 excretions. Light microscopic (LM) studies showed that rats' kidneys fed on SC containing EPO or FO were not always affected and the lesions were of minor importance. In conclusion, these results suggest that EPO (GLA) and FO (EPA) could play a beneficial role in the development or the modulation of the renal syndrome induced by CsA.


Asunto(s)
Ciclosporina/antagonistas & inhibidores , Ciclosporina/toxicidad , Ácido Eicosapentaenoico/farmacología , Riñón/efectos de los fármacos , Ácido gammalinolénico/farmacología , 6-Cetoprostaglandina F1 alfa/orina , Animales , Creatinina/metabolismo , Dinoprostona/orina , Ácidos Grasos Esenciales/farmacología , Aceites de Pescado/farmacología , Riñón/patología , Riñón/fisiopatología , Ácidos Linoleicos , Oenothera biennis , Aceites de Plantas , Prostaglandinas/metabolismo , Ratas , Ratas Wistar , Tromboxano B2/orina
3.
Artículo en Inglés | MEDLINE | ID: mdl-1561232

RESUMEN

Acute renal failure (ARF) induced with large doses of Gentamicin (GM) (an aminoglycoside) was associated with increased urinary TXB (TXA) excretion which provoked a decrease of the ratios of urinary PGE2/TXB2 and 6-keto-PGF1 alpha (PGI2)/TXB2 excretions. Furthermore, as indicated by light microscopy most of the epithelial cells lining the proximal tubules show obvious lesions varying from swelling of their cytoplasm to complete necrosis. Either the inhibitor, OKY-O46, of TXA-synthetase, or volume expansion (VE) with isotonic saline (IS) of the experimental animals diminished urinary TXB excretion which provoked 1) augmentation of the ratios of urinary PGE/TXB and 6-keto-PGF1 alpha/TXB excretions, 2) elevation of creatinine clearance (Ccr) and 3) diminution of proteinuria (PU). This protection against ARF-by OKY-O46 and VE can a can be seen in microscopic sections where necrosis of proximal tubules is almost absent. Only a few proximal tubules show swelling of their epithelial cells and some focal areas of tubule necrosis. We suggest that the metabolites of arachidonic acid (AA), TXA2 a (potent vasoconstrictor agent) and prostaglandins (PGE2 and PGI2), (potent vasodilator factors), play an important role in the development (TXA2) or in the prevention (PGs) of ARF induced by this antibiotic.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Gentamicinas/toxicidad , Tromboxano A2/biosíntesis , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/patología , Animales , Arginina Vasopresina/metabolismo , Catecolaminas/metabolismo , Femenino , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Metacrilatos/farmacología , Prostaglandinas/metabolismo , Ratas , Ratas Endogámicas , Sistema Renina-Angiotensina/efectos de los fármacos , Tromboxano-A Sintasa/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA